Skip to main content
. Author manuscript; available in PMC: 2015 Jun 15.
Published in final edited form as: Cancer. 2014 Mar 11;120(12):1890–1897. doi: 10.1002/cncr.28654

Table 2.

Percentage of patients with grade 2+ and grade 3+ paclitaxel/carboplatin-induced CIPN by CTCAE

Glutathione
(N=94)
Placebo
(N=91)
Total
(N=185)
p-value
Indicator: Grade 2+ CIPN 0.451
  No 58 (62%) 61 (67%) 119 (64%)
  Yes 36 (38%) 30 (33%) 66 (36%)
Indicator: Grade 3+ CIPN 0.771
  No 89 (95%) 87 (96%) 176 (95%)
  Yes 5 (5%) 4 (4%) 9 (5%)
1

Chi-Square test